Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Psyched：国防部。”s 氯胺酮试验、Cybin's psilocybin、代谢障碍、改革更新等
Defense Dept. Funds Ketamine Study For PTSD Treatment
国防部资助用于创伤后应激障碍治疗的氯胺酮研究
A DOD Health Agency-funded adaptive platform trial for alternative treatments for PTSD will test SLS-002 on some 600 active-duty service members and veterans. The intranasal racemic ketamine was developed by biotech company Seelos Therapeutics (NASDAQ:SEEL).
一项由国防部卫生署资助的创伤后应激障碍替代疗法适应平台试验将在大约 600 名现役军人和退伍军人身上测试 SLS-002。鼻内消旋氯胺酮由生物技术公司Seelos Therapeutics（纳斯达克股票代码：SEEL）开发。
The new Phase 2 study will use an adaptive platform trial design involving a 30-day screening period, a 12-week treatment period, and a four-week follow-up to assess safety, tolerability and efficacy of multiple doses of SLS-002 paired with therapy. Read more HERE.
新的2期研究将使用自适应平台试验设计，包括30天的筛查期、12周的治疗期和四周的随访，以评估多剂量 SLS-002 与治疗相结合的安全性、耐受性和有效性。在这里阅读更多。
Cybin's Novel Psilocybin Topline Data
Cybin 的新型 psilocybin 头条数据
Next-generation psychedelics biotech Cybin Inc...
下一代迷幻药...
登录免费看全文
登录/注册
资讯热榜
更新时间